New device aims to filter out dangerous inflammation during heart surgery

NCT ID NCT06512623

Completed Disease control Sponsor: Centre Hospitalier Universitaire Vaudois Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called HA-380® that filters inflammatory substances from the blood during heart-lung bypass in complex cardiac surgeries. Forty-one adults undergoing high-risk procedures like heart transplants or aortic dissection repairs were enrolled. The goal was to see if the device could reduce organ failure and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hemoadsorption device (HA-380® cartridge)
What this could lead to: If effective, this device could reduce inflammation-related organ failure after complex heart surgery, potentially shortening hospital stays and improving survival.
What could go wrong: This is a small, single-center trial with only 41 patients, so results may not apply broadly. The device may not show clear benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE INFECTIOUS ENDOCARDITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder infective endocarditis Inflammation inflammatory disease multiple organ dysfunction syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC DISEASE CARDIO-PULMONARY BYPASS INFLAMMATION ORGAN DYSFUNCTION SYNDROME POST-CARDIAC SURGERY

Contacts and locations

Locations

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.